[Expression and Prognostic Impact of in Bone Marrow of Patients with Newly Diagnosed Acute Myeloid Leukemia].

Objective: To detect the expression level of gene in the bone marrow of newly diagnosed patients with acute myeloid leukemia (AML) and investigate its influence on the clinical characteristics and prognosis.

Methods: The expression level of gene in the bone marrow of 90 newly diagnosed patients with AML that accompanying clinical characteristics and survival status were detected by RT-qPCR, and compared with 18 allogeneic hematopoietic stem cell transplantation (allo-HSCT) donors. The Chi-square test, Kaplan-Meier survival analysis, and Cox proportional hazards regression model were used to analyze the correlation of expression level with clinical characteristics and prognosis.

Results: Compared with allo-HSCT donors, the expression was significantly increased in newly diagnosed AML patients ( <0.01). Compared with patients with total response (OR, complete response + complete response with incomplete hematologic recovery) after 2 courses of induction chemotherapy, the expression of in patients without OR was significantly increased ( <0.05). There was a significant difference in the relative expression of between patients with and without OR after 2 courses of induction therapy ( <0.001). The median survival time of patients with high expression of was significantly shorter than that of patients with low expression of ( <0.05). The multivariate Cox proportional hazards regression analysis showed that prognostic stratification, the expression level of , and whether two courses of induction therapy achieved OR were independent factors affecting the prognosis of AML patients ( <0.05).

Conclusions: Compared with allo-HSCT donors, the expression level of gene is increased in the bone marrow of newly diagnosed AML patients. The prognosis of patients with high expression of is poor. The expression level of is an independent factor affecting the prognosis of AML patients.